Training activity information
Details
Interpret flow cytometry data for an initial diagnostic screening panel for the following conditions:
- CLL
- Myeloma
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Considerations
- Marker expression, markers of immaturity, and lineage-specific markers
- Features of malignancy in standard Immunology flow plots
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What are the characteristic immunophenotypic profiles of CLL and Myeloma as detected by flow cytometry? What are the limitations of an initial screening panel in definitively diagnosing these conditions?
- Consider the specific insights you hope to gain in recognising the flow cytometric features indicative of CLL and Myeloma. . What specific aspects of interpreting data for these conditions do you want to focus on learning?
- What steps will you take to prepare for training activity with your training officer or a senior colleague. Can you review examples of flow cytometry data from previous cases of CLL and Myeloma? Consider possible challenges you might face andhow will you approach them. What resources or further learning might help you feel more confident in this task?
In action
- When interpreting the flow cytometry data, what specific characteristics are you looking for that are indicative of CLL and Myeloma? How are you systematically analysing the data to identify these features? What decisions are you making about the presence or absence of markers and their intensity? How are you distinguishing between normal variation and potential diagnostic significance? Which aspects of interpreting flow cytometry for CLL and Myeloma feel more familiar, and which require more focused attention to specific details and marker combinations?
- What difficulties are you encountering in distinguishing between these conditions or from other potential differential diagnoses based on the initial data? What immediate learning points are emerging regarding the key immunophenotypic features of CLL and Myeloma as seen in flow cytometry? How does this interpretation connect with your understanding of the underlying biology and cellular characteristics of CLL and Myeloma?
- If the flow cytometry plots are not entirely typical, what other information or analytical approaches might you consider (even if not immediately available)? If you are uncertain about a specific aspect of the interpretation, what immediate questions would you want to ask a senior colleague?
On action
- What were your interpretations regarding the likelihood of each condition based on the initial screening panel?
- Did you enhance your ability to differentiate the typical immunophenotypic profiles of CLL and Myeloma? What were the most distinguishing features for each? Were there any unexpected findings that broadened your understanding of the variability in these conditions? How did your real-time interpretation of the data align with the expected patterns for CLL and Myeloma? Were there any instances where your initial thoughts changed as you analysed further?
- What specific aspects of flow cytometric interpretation for CLL and Myeloma screening do you want to focus on developing further? How will you use this experience to improve your analysis of future flow cytometry data for these conditions? What further learning activities will you undertake to solidify your knowledge? Are there any resources that you found particularly helpful or would like to explore further?
Beyond action
- Since interpreting these initial screening panels, have you encountered more complex flow cytometry data for CLL and Myeloma? Have you refined your interpretation skills based on these more challenging cases or further learning about the nuances of these conditions?
- How does your interpretation of screening panels in this DTA compare to how you would now approach a similar case? What key indicators have become more salient?
- Has this DTA enhanced your ability to recognise the characteristic flow cytometric features of CLL and Myeloma in initial screening? Has it made your interpretation process more efficient or accurate? How did your interpretation contribute to the subsequent diagnostic workup?
- What transferable skills (e.g., data analysis, differential diagnosis, application of disease knowledge) did you develop that will be relevant to interpreting various laboratory investigations in the future?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 2 |
Outcome
Analyse, interpret and report on laboratory investigations for haematological malignancies, including recognition of abnormal results. |